Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amazon Pharmacy Spotlights Lowest-Cost Drugs And Generic Discounts

Launches Amazon Pharmacy Service Delivering Prescription Medications In US

Executive Summary

Amazon stands to shake up the pharmacy business in the US after launching an online prescription drug delivery service that emphasizes the ability to compare prices between branded and generic drugs and choose the lowest-cost option, as well as offering discounts of up to 80% off generics prices.

You may also be interested in...



WBA not worried by Amazon PillPack deal

Walgreens Boots Alliance’s (WBA)’s chief executive officer Stefano Pessina has insisted that the firm is “not particularly worried” by online retail giant Amazon’s growing interest in the pharmacy market.

Amazon purchases PillPack

Amazon has signed a deal to acquire for an undisclosed fee PillPack, a US online pharmacy that “delivers medications in pre-sorted dose packaging, co-ordinates refills and renewals, and makes sure shipments are sent on time”. The agreement – which is subject to regulatory approvals and other customary closing conditions – is expected to close by the end of 2018.

Bio-Thera Ventures Outside China With European Bevacizumab Filing

China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel